Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 343 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT06631404Recruiting
Ultrasound test for lupus kidney activity
This trial uses an ultrasound to measure kidney blood flow in people with lupus kidney disease. The goal is to see if this simple test can tell how active the disease is, which might help doctors adjust treatment without needing frequent biopsies.
SohagAges 18–50 - NCT06642402Recruiting
Studying lupus kidney disease using urine particles
This study looks at tiny particles in urine to better understand and monitor lupus-related kidney problems. It may help find better ways to track the disease without invasive biopsies.
KoldingAges 18 years+ - NCT06682507Recruiting
Lupus nephritis long-term study
This study follows patients with lupus nephritis (kidney inflammation caused by lupus) over time to learn more about the disease and improve care. You may join if you have had a kidney biopsy confirming lupus nephritis at this hospital.
Guangzhou, GuangdongAges 14 years+ - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06717815RecruitingPhase 1/Phase 2
Study of IPG11406 for lupus kidney disease
This trial tests a new drug called IPG11406 for people with active lupus nephritis, a type of kidney inflammation caused by lupus. It aims to see if the drug can help reduce kidney damage and improve symptoms.
Hefei, AnhuiAges 18–70 - NCT06841042RecruitingPhase 1/Phase 2
Testing a new drug for active lupus
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
BeijingAges 18–75 - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06943937RecruitingPhase 1
Cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07225387RecruitingPhase 4
Belimumab and voclosporin for lupus kidney disease
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Glendale, ArizonaAges 18–80 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT07260942Recruiting
Study of ferroptosis in lupus
This study looks at whether a type of cell death called ferroptosis plays a role in lupus. Participants with lupus or with rheumatoid arthritis or inflammatory bowel disease will be compared to understand more about how lupus works.
BordeauxAges 18 years+ - NCT07282392Recruiting
Emotional awareness therapy for lupus and fibromyalgia pain
This study tests if a therapy called Emotional Awareness and Expression Therapy (EAET) can help people with lupus and fibromyalgia or chronic widespread pain feel better by addressing emotional factors that may worsen their pain. You would attend sessions to learn how to understand and express your emotions in healthy ways.
Salt Lake City, UtahAges 18–65 - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07313475Recruiting
Testing a new tool to detect lupus anticoagulant
This trial checks if a new method (Cryocheck HexLA Integrated TCA) can accurately find lupus anticoagulant in blood samples. Your leftover blood from regular tests may be used, and it requires no extra visits.
StrasbourgAges 18 years+ - NCT07323173RecruitingPhase 1
Testing LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy volunteers and in people with mild-to-moderate lupus. The goal is to see if it is safe and how the body handles it.
Bengbu, AnhuiAges 18–60 - NCT07323524RecruitingPhase 4
Dapagliflozin for active lupus kidney disease
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Boston, MassachusettsAges 18–70 - NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 343 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.